Health Catalyst slips; Piper Sandler downgrades to 'neutral'

Health Catalyst

27/08/2025 11:47

** Shares of healthcare tech firm Health Catalyst HCAT.O down 3.7% at $3.37 premarket

** Piper Sandler downgrades stock to "neutral" from "overweight"

** Cuts target price to $4 from $8, implying a 14.3% premium from the stock's last close

** Piper cites lack of organic growth drivers that can indicate revenue growth recovery and create shareholder value

     ** Notes, the CY25 revenue "guide-down removes all organic growth from the outlook and HCAT now expects CY26 revenue to decline y/y"

** HCAT cut its CY2025 revenue outlook to $310 million from its previous forecast of $335 million

** Average rating of 12 analysts is "hold", with a median PT of $5 - data compiled by LSEG

** As of last close, HCAT down nearly 51% YTD

 (Reporting by Kanchana Chakravarty in Bengaluru)

 ((Kanchana.Chakravarty@thomsonreuters.com))